B. Paguet

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

M. Lebwohl, A. Blauvelt, J. Bagel, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial

I. Hampele, J. Szepietowski, B. Sigurgeirsson, 2021, Dermatologic therapy.

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *

K. Reich, M. Augustin, G. Bruin, 2022, The British journal of dermatology.

Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial

I. Hampele, J. Szepietowski, B. Sigurgeirsson, 2021, Dermatologic therapy.